IMEVE S/A
IMEVE S/A is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at IMEVE S/A.
IMEVE S/A is a company.
Key people at IMEVE S/A.
IMEVE S/A (Imeve - Indústria de Medicamentos Veterinários S.A.) is a 100% Brazilian biotechnology company specializing in animal health and nutrition, developing probiotic additives, medicines, supplements, hygiene products, and pet solutions to enhance animal wellbeing.[2][3][4] Headquartered in Jaboticabal, São Paulo, with over 6,000 m² of facilities including state-of-the-art labs, it operates in the pharmaceutical-veterinary manufacturing sector, serving livestock, pets, and animal feed markets while adhering to Good Manufacturing Practices (GMP) standards.[1][2][4] The company employs around 90 people and has shown steady growth, with total assets increasing 3.05% recently.[1][3]
Founded in January 1980 (with formal establishment on March 4), IMEVE S/A began as a veterinary pharmaceuticals manufacturer in Jaboticabal, Brazil, focusing on animal health innovations amid growing demand for biotech solutions in agriculture and pet care.[1][2][4] Early development emphasized research into probiotics and supplements, expanding from core medicines to a broader portfolio of high-value animal nutrition products.[2][3] A pivotal moment came in 2011 when Criatec, Brazil's largest innovation-focused venture capital fund, acquired a minority stake to fuel growth in biotechnology; Criatec later sold its stake to private shareholders in a transaction advised by Lincoln International, marking IMEVE's transition to private ownership.[3]
IMEVE rides the global trend of biotechnology in animal health, driven by rising demand for probiotics, supplements, and sustainable nutrition amid intensifying agribusiness and pet care markets in Brazil and emerging economies.[2][3] Timing aligns with Brazil's agricultural boom and post-2011 VC infusion from Criatec, which targeted biotech innovations in healthcare and industrials, enabling scale-up in a sector facing regulatory pressures for GMP-compliant products.[1][3][4] Favorable market forces include export growth and investor interest in animal wellbeing tech, positioning IMEVE to influence Brazil's veterinary pharma ecosystem through R&D leadership and private capital transitions.[3][6]
IMEVE is poised for expansion in probiotic and supplement innovation, leveraging its GMP-certified facilities and export capabilities to capture more of Latin America's animal health market.[2][3][6] Trends like sustainable agrotech, pet humanization, and biotech advancements in feed efficiency will shape its trajectory, potentially attracting new private investments post-Criatec exit.[3] Its influence may evolve from niche manufacturer to regional biotech leader, building on 45 years of stability to drive animal nutrition breakthroughs that started in Jaboticabal's labs.
Key people at IMEVE S/A.
